Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer
In addition to each of the factors that govern the identification of a successful oncology drug candidate, drug discovery aimed at treating neurological cancer must also consider the presence of the blood–brain barrier (BBB). The high level of expression of efflux transporters (e.g., P-glycoprotein...
Gespeichert in:
| Veröffentlicht in: | Journal of medicinal chemistry 2016-11, Vol.59 (22), p.10030-10066 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 10066 |
|---|---|
| container_issue | 22 |
| container_start_page | 10030 |
| container_title | Journal of medicinal chemistry |
| container_volume | 59 |
| creator | Heffron, Timothy P |
| description | In addition to each of the factors that govern the identification of a successful oncology drug candidate, drug discovery aimed at treating neurological cancer must also consider the presence of the blood–brain barrier (BBB). The high level of expression of efflux transporters (e.g., P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp)) at the BBB limits many small molecules from freely reaching the brain, where neurooncologic malignancies reside. Furthermore, many of the targets identified for the potential treatment of central nervous system (CNS) malignancies suggest that kinase inhibitors, capable of penetrating the BBB to reach their target, would be desirable. This Perspective discusses the unmet need for neurooncology treatments, the appeal of kinase targets in this space, and a summary of what is known about free brain penetration of clinical inhibitors of kinases that are of interest for the treatment of brain cancer. |
| doi_str_mv | 10.1021/acs.jmedchem.6b00618 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1826718275</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1826718275</sourcerecordid><originalsourceid>FETCH-LOGICAL-a414t-10fcdbf7556742d5e0e58e03b50c5085b8dcb20ee88e6f4817b8a90e27eaf8243</originalsourceid><addsrcrecordid>eNp9kDtPwzAQxy0EoqXwDRDyyJJyduzYjFDxqChioMyW7Z7VVHkUOxn49gTaMrLcDfd_6H6EXDKYMuDsxvo03dS48musp4UDKJg-ImMmOWRCgzgmYwDOM17wfETOUtoAQM54fkpGXAkmoFBjcv9e26qir22Fvq-QvpSNTUjnzbp0ZdfGREMbabdGuoxouxqbjraB3kdbNnRmG4_xnJwEWyW82O8J-Xh8WM6es8Xb03x2t8jsUNZlDIJfuaCkLJTgK4mAUiPkToKXoKXTK-84IGqNRRCaKaftLSBXaIPmIp-Q613uNrafPabO1GXyWFW2wbZPhmleqGEoOUjFTupjm1LEYLaxrG38MgzMDz0z0DMHemZPb7Bd7Rt6N9z-TAdcgwB2gl9728dmePj_zG97Zn3L</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1826718275</pqid></control><display><type>article</type><title>Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer</title><source>MEDLINE</source><source>ACS Publications</source><creator>Heffron, Timothy P</creator><creatorcontrib>Heffron, Timothy P</creatorcontrib><description>In addition to each of the factors that govern the identification of a successful oncology drug candidate, drug discovery aimed at treating neurological cancer must also consider the presence of the blood–brain barrier (BBB). The high level of expression of efflux transporters (e.g., P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp)) at the BBB limits many small molecules from freely reaching the brain, where neurooncologic malignancies reside. Furthermore, many of the targets identified for the potential treatment of central nervous system (CNS) malignancies suggest that kinase inhibitors, capable of penetrating the BBB to reach their target, would be desirable. This Perspective discusses the unmet need for neurooncology treatments, the appeal of kinase targets in this space, and a summary of what is known about free brain penetration of clinical inhibitors of kinases that are of interest for the treatment of brain cancer.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/acs.jmedchem.6b00618</identifier><identifier>PMID: 27414067</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Animals ; Antineoplastic Agents - chemistry ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Brain Neoplasms - drug therapy ; Brain Neoplasms - enzymology ; Humans ; Molecular Structure ; Protein Kinase Inhibitors - chemistry ; Protein Kinase Inhibitors - pharmacology ; Protein Kinase Inhibitors - therapeutic use ; Protein Kinases - metabolism ; Small Molecule Libraries - chemistry ; Small Molecule Libraries - pharmacology ; Small Molecule Libraries - therapeutic use</subject><ispartof>Journal of medicinal chemistry, 2016-11, Vol.59 (22), p.10030-10066</ispartof><rights>Copyright © 2016 American Chemical Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a414t-10fcdbf7556742d5e0e58e03b50c5085b8dcb20ee88e6f4817b8a90e27eaf8243</citedby><cites>FETCH-LOGICAL-a414t-10fcdbf7556742d5e0e58e03b50c5085b8dcb20ee88e6f4817b8a90e27eaf8243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.6b00618$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00618$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,780,784,2765,27076,27924,27925,56738,56788</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27414067$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Heffron, Timothy P</creatorcontrib><title>Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>In addition to each of the factors that govern the identification of a successful oncology drug candidate, drug discovery aimed at treating neurological cancer must also consider the presence of the blood–brain barrier (BBB). The high level of expression of efflux transporters (e.g., P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp)) at the BBB limits many small molecules from freely reaching the brain, where neurooncologic malignancies reside. Furthermore, many of the targets identified for the potential treatment of central nervous system (CNS) malignancies suggest that kinase inhibitors, capable of penetrating the BBB to reach their target, would be desirable. This Perspective discusses the unmet need for neurooncology treatments, the appeal of kinase targets in this space, and a summary of what is known about free brain penetration of clinical inhibitors of kinases that are of interest for the treatment of brain cancer.</description><subject>Animals</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Brain Neoplasms - drug therapy</subject><subject>Brain Neoplasms - enzymology</subject><subject>Humans</subject><subject>Molecular Structure</subject><subject>Protein Kinase Inhibitors - chemistry</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Protein Kinases - metabolism</subject><subject>Small Molecule Libraries - chemistry</subject><subject>Small Molecule Libraries - pharmacology</subject><subject>Small Molecule Libraries - therapeutic use</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kDtPwzAQxy0EoqXwDRDyyJJyduzYjFDxqChioMyW7Z7VVHkUOxn49gTaMrLcDfd_6H6EXDKYMuDsxvo03dS48musp4UDKJg-ImMmOWRCgzgmYwDOM17wfETOUtoAQM54fkpGXAkmoFBjcv9e26qir22Fvq-QvpSNTUjnzbp0ZdfGREMbabdGuoxouxqbjraB3kdbNnRmG4_xnJwEWyW82O8J-Xh8WM6es8Xb03x2t8jsUNZlDIJfuaCkLJTgK4mAUiPkToKXoKXTK-84IGqNRRCaKaftLSBXaIPmIp-Q613uNrafPabO1GXyWFW2wbZPhmleqGEoOUjFTupjm1LEYLaxrG38MgzMDz0z0DMHemZPb7Bd7Rt6N9z-TAdcgwB2gl9728dmePj_zG97Zn3L</recordid><startdate>20161123</startdate><enddate>20161123</enddate><creator>Heffron, Timothy P</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20161123</creationdate><title>Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer</title><author>Heffron, Timothy P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a414t-10fcdbf7556742d5e0e58e03b50c5085b8dcb20ee88e6f4817b8a90e27eaf8243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Brain Neoplasms - drug therapy</topic><topic>Brain Neoplasms - enzymology</topic><topic>Humans</topic><topic>Molecular Structure</topic><topic>Protein Kinase Inhibitors - chemistry</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Protein Kinases - metabolism</topic><topic>Small Molecule Libraries - chemistry</topic><topic>Small Molecule Libraries - pharmacology</topic><topic>Small Molecule Libraries - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Heffron, Timothy P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Heffron, Timothy P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2016-11-23</date><risdate>2016</risdate><volume>59</volume><issue>22</issue><spage>10030</spage><epage>10066</epage><pages>10030-10066</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><abstract>In addition to each of the factors that govern the identification of a successful oncology drug candidate, drug discovery aimed at treating neurological cancer must also consider the presence of the blood–brain barrier (BBB). The high level of expression of efflux transporters (e.g., P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp)) at the BBB limits many small molecules from freely reaching the brain, where neurooncologic malignancies reside. Furthermore, many of the targets identified for the potential treatment of central nervous system (CNS) malignancies suggest that kinase inhibitors, capable of penetrating the BBB to reach their target, would be desirable. This Perspective discusses the unmet need for neurooncology treatments, the appeal of kinase targets in this space, and a summary of what is known about free brain penetration of clinical inhibitors of kinases that are of interest for the treatment of brain cancer.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>27414067</pmid><doi>10.1021/acs.jmedchem.6b00618</doi><tpages>37</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-2623 |
| ispartof | Journal of medicinal chemistry, 2016-11, Vol.59 (22), p.10030-10066 |
| issn | 0022-2623 1520-4804 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1826718275 |
| source | MEDLINE; ACS Publications |
| subjects | Animals Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Brain Neoplasms - drug therapy Brain Neoplasms - enzymology Humans Molecular Structure Protein Kinase Inhibitors - chemistry Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Protein Kinases - metabolism Small Molecule Libraries - chemistry Small Molecule Libraries - pharmacology Small Molecule Libraries - therapeutic use |
| title | Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T02%3A01%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Small%20Molecule%20Kinase%20Inhibitors%20for%20the%20Treatment%20of%20Brain%20Cancer&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Heffron,%20Timothy%20P&rft.date=2016-11-23&rft.volume=59&rft.issue=22&rft.spage=10030&rft.epage=10066&rft.pages=10030-10066&rft.issn=0022-2623&rft.eissn=1520-4804&rft_id=info:doi/10.1021/acs.jmedchem.6b00618&rft_dat=%3Cproquest_cross%3E1826718275%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1826718275&rft_id=info:pmid/27414067&rfr_iscdi=true |